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Objectives. The aim of this study was to evaluate the hemody- 
namic effect of L-arginine infusion in patients with congestive 
heart failure. 
Background. Endothelium-dependent vasodilation is impaired 
in patients with congestive heart failure. Nitric oxide, which was 
identified as endothelium-derived relaxing factor, is generated by 
nitric oxide synthase from L-arginine. Our hypothesis was that 
administration of L-arginine in patients with congestive heart 
failure may increase nitric oxide production and have a beneficial 
hemodynamic effect. 
Methods. Twelve patients with congestive heart failure (New 
York Heart Association class II or HI) due to coronary artery 
disease (left ventricular ejection fraction <35%) were given 20 g of 
L-arginine by intravenous infusion over 1 h at a constant rate. 
Stroke volume, cardiac output and left ventricnlar ejection frac- 
tion were determined with Doppler echocardiography at baseline 
and at 30 and 60 rain and I h after the end of infusion. Blood and 
urinary levels of nitrite/nitrate (NOJNO3) , stable metabolites of 
nitric oxide, were measured and clearance was calculated. 
Results. One hour of infusion of L-arginine resulted in a 
significant increase in stroke volume (from 68 + 18 ml to 76 -+ 
23 ml [mean ± SD], p = 0.014) and cardiac output (from 4.07 -+ 
1.22 liters/rain to 4.7 -+ 1.42 liters/rain, p = 0.006) without a 
change in heart rate. Mean arterial blood pressure decreased 
(from 102 -+ 11 mm Hg to 89 -+ 9.5 mm Hg, p < 0.002), and 
systemic vascular resistance decreased significantly. Within 1 h 
after cessation of L-arginine infusion, blood pressure, stroke 
volume, cardiac output and systemic vascular resistance were 
statistically not different from baseline values. Clearance of 
NOJNO3 increased significantly during L-arginine administra- 
tion (from 13.28 + 0.42 ml/min to 29.97 -+ 1.09 ml/min, p < 0.001). 
Conclusions. Infusion of L-arginine in patients with conges- 
tive heart failure results in increased production of nitric 
oxide, peripheral vasodilation and increased cardiac output, 
suggesting a beneficial hemodynamic and possibly therapeutic 
profile. 
(J Am CoU Cardiol 1995;26:1251-6) 
Endothelial dysfunction may be responsible for impaired va- 
sodilation of the peripheral vasculature in patients with con- 
gestive heart failure (1-4). The endothelium participates in the 
regulation of vascular tone by producing vasoactive substances 
(5,6). The endothelium-derived r laxing factor, which was 
identified as nitric oxide, is generated by nitric oxide synthase, 
which converts the amino acid t.-arginine to nitric oxide 
through oxidation of the guanidinium nitrogen. Nitric oxide 
stimulates guanylate cyclase in vascular smooth muscle cells, 
resulting in relaxation and vasodilation (7). This stimulation 
results in elevation of cyclic guanosine monophosphate, which 
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affects physiologic processes such as control of vascular tone, 
platelet inhibition and neurotransmission (7,8). 
Administration of vasodilators, such as nitrates, hydralazine or 
angiotensin-converting e zyme inhibitors, results in marked he- 
modynamic mprovement in patients with congestive heart failure 
(8-10). Long-term studies (11-13) have demonstrated improved 
exercise performance, functional class and survival when vasodi- 
lators are given to patients with congestive heart failure. Recently, 
several studies (1-4,14,15) using invasive methods have proved 
that endothelium-dependent vasodilation is impaired in patients 
with congestive heart failure. Administration of L-arginine to 
these patients may increase nitric oxide production with conse- 
quent beneficial hemodynamic effects and thus prove to be an 
effective new therapeutic approach (16). 
The purpose of this study was to evaluate the immediate 
hemodynamic response to intravenous L-arginine administra- 
tion in patients with heart failure with the use of noninvasive 
echocardiographic studies and to correlate the response with 
changes in blood and urinary nitrite/nitrate (NO2/NO3) , which 
are stable metabolites of nitric oxide (17,18). 
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Table 1. Clinical Profiles of Patients 
Pt Age (yr)/ NYHA Risk 
No. Gender LVEF ((:i) Class Factors 
1 70/M 33 II D. S 
2 57/F 22 II C 
3 56/M 27 III S 
4 54/M 24 III D, H 
5 56/M 14 11 C 
6 57/M 24 II C 
7 78/M 30 III S 
8 67/M 30 III S 
9 62/M 13 I I C 
l0 63/M 14 II D, S 
11 71/M 22 llI D, H. S 
12 61/M 27 II C 
C = hypercholesterolemia; D = diabetes mellitus; F - female; H = 
hypertension; LVEF = left ventricular ejection fraction by radionuclide angiog- 
raphy; M - male; NYHA Class = New York Heart Association heart failure 
class; Pt = patient; S - smoking. 
Methods  
Patients (Table 1). Twelve patients with congestive heart 
failure without clinical or echocardiographic evidence of pri- 
mary valvular heart disease participated in the study. The 
nature and potential risks and benefits of the study were 
explained, and all patients agreed to participate in the study 
and signed an informed consent form approved by the Inves- 
tigational Review Board of the Tel Aviv Medical Center and 
Israeli Ministry of Health. All patients had congestive heart 
failure due to ischemic heart disease and previous myocardial 
infarction. The group comprised l 1 men and 1 woman with an 
age range of 55 to 78 years. All patients had New York Heart 
Association functional class II or III heart failure and were 
admitted to the coronary care unit for the study. Left ventric- 
ular ejection fraction by radionuclide angiography was <35% 
(range 13% to 33%) in all patients. All patients had sinus 
rhythm, and none had active anginal syndrome, recent myo- 
cardial infarction, coronary artery bypass urgery or any sys- 
temic chronic disease. Doppler echocardiography, performed 
before the study to ensure adequate visualization, showed mild 
functional mitral regurgitation i  3 of the 12 patients. 
All patients were treated with digitalis and furosemide, 
which were withheld on the day of the study. Nine patients 
were receiving angiotensin-converting e zyme inhibitors, and 
none of the 12 had been given any vasodilators for 24 h before 
the study. The study was performed after overnight fasting. 
Noninvasive hemodynamic studies. An Acuson ultrasound 
imaging system (128/5XP, USA) was used for both imaging 
and Doppler flow studies. Two-dimensional echocardiographic 
images were obtained with 2.5- or 3.5-MHz transducers, de- 
pending on which provided optimal visualization of the endo- 
cardium. For volume stimation the apical four-chamber view 
was used as described by Schnittger et al. (19) and Gordon et 
al. (20) and previously used by us (21,22). Maximal effort was 
made to ensure maximal length and width of the left ventricle. 
The interval between the end of the baseline study and the 
intervention study was 30 and 60 min. A separate control study 
was performed at 120 rain, 60 rain after the end of the 
intervention. Images were accepted for analysis if ->75% of the 
endocardium was seen. 
Tracing was performed with a built-in computer program 
for single-plane area-length volume calculations and Simpson's 
rule computation from tracings of the ventricular outlines. Left 
ventricular volumes were measured at end-diastole (i.e., larg- 
est dimension or onset of the QRS complex) and at end-systole 
(i.e., smallest dimension or one frame before opening of the 
mitral valve). Left ventricular ejection fraction was calculated 
from end-diastolic volume (EDV) and end-systolic volume 
(ESV) by the standard formula: LVEF = (EDV - ESV)/ 
EDV. 
Forward aortic flow by pulsed Doppler echocardiography. 
For the recording of left ventricular outflow at the level of the 
aortic annulus, the transducer was placed at the apical position 
and rotated toward the long-axis or hemiaxial view. The 
sample volume was placed in the middle of the left ventricular 
outflow tract immediately proximal to the leaflet of the aortic 
valve, as described by Lewis et al. (23). 
Forward stroke volume was determined as the product of 
the time-velocity integral (average of five cardiac ycles) and 
the cross-sectional area of the aortic annulus. Curves of highest 
peak velocities were selected. The average of the time-velocity 
integral was obtained by tracing the contour of the darkest 
portion of the outflow tract curve. The cross-sectional rea of 
the aortic annulus was calculated as m 2, where r represents 
half of the annular diameter measured from the parasternal 
long-axis view immediately proximal to the points of insertion 
of the aortic leaflets after maximal systolic outflow separation. 
All Doppler and echocardiographic analyses were performed 
by two operators who did not know at which stage of the study 
the recording was obtained. Systemic vascular resistance 
(SVR) was calculated by using standard formula and the 
following variables: forward stroke volume (FSV), heart rate, 
derived cardiac output (CO), mean blood pressure (MBP) and 
central venous pressure stimated from jugular venous pres- 
sure (JVP). The formula used was: SVR = (MBP - JVP) × 
80/CO in dynes.s.cm -5.
Study protocol. Drug administration. After the basal 
Doppler echocardiographic study, blood sampling and a 2-h 
urine collection were performed. A continuous 1-h infusion 
100 ml of 5% glucose mixed with 100 ml of 20% solution of 
L-arginine hydrochloride was performed through the periph- 
eral vein; a total of 20 g of L-arginine was administered at
a constant rate. The study was conducted in a quiet, 
temperature-controlled room with the patients resting in the 
supine position. Heart rate and blood pressure were recorded 
every 10 rain during the study. 
Blood samples were obtained and a Doppler echocardio- 
graphic study was repeated at baseline, at 30 and 60 min during 
drug administration and at 60 min after cessation of the 
infusion. Urine was collected immediately before and at the 
end of L-arginine administration and 60 rain later. In all 
urinary and blood samples, NOz/NO3, creatinine and sodium 
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Table 2. Hemodynamic and Echocardiographic Findings Before and After L-Arginine Infusion 
Infusion 
After Infusion 
Baseline 30 rain 60 rain (120 rain) 
SV (ml)*~: 68 + 18 74 : 201 76 + 231 73 ± 26 
HR (beats/'min) 60 _+ 7 61.6 : 9 61.2 _+ 9 60.5 = 8 
CO (liters/min)$ 4.07 ± 1.22 4.54 + 1.4411 4.7 _+ 1.4211 4.4 = 1.57 
MBP (ram Hg)§ 102 ± 11 90 + 1311 89 = 9.511 101 ± 11 
TPR (dynes-s.cm-5)§ 1.926 _+ 515 1521 ~ 4201[ 1,452 _+ 36711 1,834 ± 637 
EF (%) 33 ± 6 35 _- 4.5 36 : 4.8 34 ± 4.4 
*p value by analysis of variance with repeated measurements: ~p 0.17; {p = 0.014; §p < 0.0001. ]lSignificant 
difference from baseline value by paired Student t test with Bonferroni correction. All values are expressed as mean value 
+ SD. CO = cardiac output: EF = left ventricular ejection fraction, calculated tYom two-dimensional echocardiography; 
HR - heart rate: MBP = mean blood pressure: SV stroke volume: TPR = total peripheral resistance. 
levels were determined. Creatinine clearance was calculated. 
Urinary and blood NO 2 and NO 3 were determined as previ- 
ously described (18). After the reduction of NO3 to NO2 by a 
90-rain incubation in a tilting bath (37°C) using nitrate reduc- 
tase from Escherichia coli (prepared by our laboratory) and 
beta-nicotinamide adenine dinucleotide phosphate (reduced 
form) (Sigma) as cofactor, the NO2 was determined with 
Griess reagent. 
Statistical analysis. The results are expressed as mean 
value _+ SD. The data were computerized (SPSS/PC+) and 
analysis of variance with repeated measurements for the 
changes in the different variables was performed. Differences 
were considered statistically significant at p < 0.05. A paired 
Student t test with Bonferroni correction was used to compare 
two time data points of the same variable. 
Results 
Table 2 shows the changes in the hemodynamic variables 
studied. Intravenous administration of L-arginine resulted in 
significant changes (analysis of variance with repeated mea- 
surements) in stroke volume (p = 0.017), cardiac output (p = 
0.014), mean blood pressure (p < 0.0001) and total peripheral 
resistance (p < 0.0001). Stroke volume increased from 68 +_ 
18 ml to 74 _+ 20 ml at 30 rain (p = 0.012) and 76 _+ 23 ml at 
60 rain (p = 0.014) after the initiation of l=arginine infusion. 
There were no significant changes in heart rate. Cardiac output 
increased from 4.07 +_ 1.22 liters/min to 4.54 _+ 1.44 liters/rain 
at 30 rain (p = 0.003) and to 4.7 +_ 1.42 liters/rain at 60 rain 
(p = 0.006). One hour after drug administration stroke volume 
and cardiac output were not significantly different from base- 
line. 
The mean blood pressure decreased from 102 + 11 mm Hg 
to 90 _+ 13 mm Hg at 30 rain (p < 0.0001) and 89 + 9.5 mm Hg 
at 60 rain (p = 0.002) and returned to the baseline value 1 h 
after drug administration. Peripheral vascular esistance de- 
creased uring L-arginine infusion from 1,926 _+ 515 to 1,521 _+ 
420 dynes.s.cm s at 30 rain (p < 0.0001) and 1,452 _+ 367 
dynes.s.cm '5 at 60 min (p < 0.0001). On cessation of k- 
arginine administration, peripheral vascular resistance in- 
creased to 1,834 _+ 637 dynes, s. cm 5. The increase in stroke 
volume and cardiac output was not associated with an increase 
in heart rate. Left ventricular ejection fraction calculated from 
echocardiographic leftventricular volumes, tended to increase 
during L-arginine infusion from 33 _+ 6% to 36 _+ 5% (p = NS). 
Nitrite/nitrate changes (Table 3). The changes in the uri- 
nary nitric oxide excretion and the nitric oxide clearance (by 
analysis of variance with repeated measurement) were statis- 
tically significant, p = 0.042 and p < 0.0001, respectively. 
Blood levels of NO2/NO 3 did not change significantly through- 
out the study period. NOz/NO 3 urinary excretion (nmol/mg 
creatinine) increased significantly to 1.48 _+ 1.09 from the 
preinfusion value of 0.84 _+ 0.42, p < 0.01). Sixty minutes after 
the end of L-arginine administration the mean value of NOJ 
NO3 excretion remained higher than the preinfusion value 
(p = NS). The NOe/NO3 clearance data showed a twofold 
increase (p < 0.001) during k-arginine infusion over the 
baseline value (29.97 + 1.09 vs. 13.28 _+ 0.42 ml/min). This 
Table 3. Changes in NO2/NO 3 After Intravenous l,-Argininc Infusion 
Baseline 
After 
Infusion Infusion 
(60 min) (120 min) 
Blood NO (nmol,'mg creatinine ) 
Urina U NO (NO_, * NO3) (#tool/liter)*) 
NO~ + NO (ml/min) clearanceS. 
53.7 +_ 18.1 48.2 ± 15.4 5 ~,..._ "~ + 13.6 
0.84 ± 0.42 1.48 = 1.09§ 1.37 ± 1.31 
13.28 + (I.42 29.97 = 1.09{} 17.73 + 1.31 
*p value by analysis of ~ariance with repeated measurements: -p 0.042: :[:p < 0.(R)01. §Significantly different from 
baselinc value by paired Student  test with Bonferroni correction. All values arc expressed as mean value : SD. NO = 
nitric oxide: NO#NO~ = nitrite:nitrate. 
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mean clearance value at 60 rain after termination of L-arginine 
infusion was higher than the preinfusion value (p = NS). 
Discuss ion  
In the present study, noninvasive methods were used to 
estimate the hemodynamic response and left ventricular per- 
formance during administration of c-arginine, the substrate of 
nitric oxide, to patients with moderate congestive heart failure. 
Infusion of 20 g of L-arginine at a steady rate over 1 h resulted 
in increased stroke volume and cardiac output with a concom- 
itant decrease in total peripheral resistance without accelera- 
tion in heart rate. Urinary excretion and clearance of NO2/ 
NO 3, both indicating an increased production of nitric oxide, 
were significantly elevated uring L-arginine administration. 
L-arginine, whether given intravenously or intraarterially, 
can reduce vascular tone (24-26). The mechanism by which it 
exerts its vasodilator effect is controversial (26). The main 
underlying mechanism seems to be the L-arginine-nitric oxide 
synthase-nitric oxide pathway. However, other possible mech- 
anisms are volume expansion with increased atrial natriuretic 
peptide and insulin levels during c-arginine infusion and the 
hypertonicity ofthe c-arginine solution. Nitric oxide also seems 
to modulate sympathetic neurotransmission at the prejunc- 
tional level in the isolated perfused rat heart (27). Enhance- 
ment of the endothelial production of nitric oxide is the 
most likely underlying mechanism for the beneficial effect of 
c-arginine on the ischemic reperfused heart (28). 
It is less plausible that the infusion of L-arginine in our 
patients caused an improved contractility of the ischemic 
myocardium by a direct intracellular metabolic effect. Stimu- 
lated nitric oxide synthase activity and a high nitric oxide level 
were found to cause hypocontractility n cardiac myocytes (29). 
Furthermore, improved contractility should have resulted in a 
significant increase in left ventricular ejection fraction, which 
was not observed in our study. The hemodynamic changes 
found in our study are similar to those observed with other 
known vasodilators given to patients with congestive heart 
failure. 
The syndrome of congestive heart failure is characterized 
by left ventricular dysfunction and reduced exercise capacity 
(30). The syndrome volves with time after the initial insult to 
the myocardium and is associated with activation of neurohu- 
moral systems, fluid accumulation, limitation of peripheral 
circulation and end-organ failure, presenting the clinical syn- 
drome of congestive heart failure (1,31). In recent years it has 
become apparent that symptoms and reduced exercise capacity 
do not necessarily relate to the severity of left ventricular 
dysfunction (32,33). Important myocardial and peripheral 
adaptive processes occur and patients may remain relatively 
asymptomatic for a prolonged period despite markedly de- 
pressed ejection fraction. Over time, the myocardium changes 
in shape, and enlarges through a process of remodeling. This 
process is associated with myocyte hypertrophy and excessive 
fibrosis (34,35). 
There are substantial data to indicate that neuroendocrine 
activation including activation of the sympathetic nervous 
system and arginine vasopressin contribute to excessive sys- 
temic vascular esistance and heightened impedance to left 
ventricular ejection, thereby contributing to worsening pump 
function in patients with congestive heart failure (31,36-38). 
Endothelial function in congestive heart failure. Recently 
it has been recognized (5-7,14) that substances derived from 
endothelial cells take part in the regulation of vascular tone. 
Nitric oxide formed from L-arginine is the endogenous nitro- 
vasodilator, which is released under basal conditions and in 
response to shear forces, local hormones, neurohumoral me- 
diators and platelet-derived products (7,16). In addition, the 
endothelium is a source of contracting factors such as 
endothelin-1, cyclooxygenase products, and possibly angioten- 
sin II (6,39,40). Alteration in endothelium-dependent vascular 
regulation occurs in clinical and experimental congestive heart 
failure. The stimulation of endothelial L-arginine pathway by 
acetylcholine is blunted, whereas the production of potent 
vasoconstrictor endothelin is augmented (1,39,41). These al- 
terations in endothelial function could contribute to the 
changes of the peripheral circulation in congestive heart 
failure. In the forearm circulation of patients with congestive 
heart failure, the vasodilator effects of acetylcholine and 
metacholine, both of which act on muscarinic receptors, are 
blunted (134,16). 
The impaired endothelium-dependent r sponse to acetyl- 
choline appears independent of the etiology of heart failure. In 
the human femoral artery, the acetyicholine-induced increase 
in blood flow is abolished in most patients with congestive 
heart failure, and the response to nitroglycerin is attenuated 
(4,14). In the femoral artery of dogs with pacing-induced 
congestive heart failure, the acetylcholine-induced increase in 
diameter is attenuated whereas the response to nitroglycerin is 
not reduced (15). Similarly, in the coronary circulation of 
patients with dilated cardiomyopathy, the increase in coronary 
blood flow in response to acetylcholine is reduced, whereas the 
effects of adenosine, an endothelium-independent vasodilator, 
are only slightly diminished (3). 
The cardiac and hemodynamic responses to load alteration 
and to administration of vasodilators were extensively studied 
in patients with impaired left ventricular function and conges- 
tive heart failure. Reduction in aflerload and an optimal 
preload are the hallmarks of vasodilator therapy in congestive 
heart failure. Immediate hemodynamic improvement, with 
increased stroke volume, cardiac output and decreased total 
peripheral resistance, were shown by various vasodilators given 
to patients with congestive heart failure (8-10). 
In the early and late stages of cardiovascular disease, both 
basal and stimulated release of endothelial mediators can be 
affected. The local endogenous vasodilator system may be 
highly important in trying to maintain tissue perfusion and 
antagonize neurohumoral vasoconstrictor f rces. In our study, 
increased availability of c-arginine, by intravenous infusion, 
resulted in augmented secretion of nitric oxide, marked 
peripheral vasodilation and improved cardiac output. Thus, the 
constitutive nitric oxide synthase can be stimulated by the higher 
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availability of its substrate. The inducible form of the enzyme 
can be activated by various pharmacologic probes such as 
acetylcholine and metacholine (42,43), agents that were not 
used in our study. Recently, L-arginine was shown to augment 
acetylcholine-induced vasodilation in patients with hypercho- 
lesterolemia (44) and to improve the magnitude of maximal 
vasodilation induced by acetylcholine and vasodilation during 
peak reactive hyperemia in patients with congestive heart 
failure but not in control subjects (16). 
Limitations of the study. Certain limitations of our study, 
in both the methods and the pathophysiologic onclusions, 
should be addressed. The study was nonrandomized and 
uncontrolled, and the study group comprised only 12 patients. 
The methods of measurements were noninvasive, the hemo- 
dynamic changes were relatively small and the effect of 
L-arginine was not evaluated in a dose-response manner. We 
(21,22) have previously compared Doppler echocardiography 
with thermodilution techniques in multiple studies to assess 
the hemodynamic response to load alterations, vasodilators 
and inotropic agents. On the basis of this experience and that 
of other groups (23,45,46), we believe that in short-term 
hemodynamic studies, Doppler echocardiographic results are 
as accurate as thermodilution data and provide significant 
information regarding directional changes. 
There are no published data regarding long-term adminis- 
tration of L-arginine in patients with congestive heart failure. 
In light of the impairment of endothelial-dependent vasodila- 
tion in these patients and the immediate beneficial effect of 
intravenous k-arginine, it would be interesting to evaluate in a 
controlled manner the immediate hemodynamic and long-term 
clinical response to oral therapy with k-arginine. 
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